Open access
190
Views
8
CrossRef citations to date
0
Altmetric
Original Research
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
Max Schlueter1 IQVIA, Real World Evidence, LondonN1 9JY, UKCorrespondence[email protected]
, Elaine Finn1 IQVIA, Real World Evidence, LondonN1 9JY, UK
, Silvia Díaz2 Lilly Spain, Health Outcomes & RWE, Alcobendas28108, Spain
, Tatiana Dilla2 Lilly Spain, Health Outcomes & RWE, Alcobendas28108, Spain
, José Inciarte-Mundo3 Lilly Spain, Medical, Alcobendas28108, Spain
& Walid Fakhouri4 Lilly, Global Patient Reported Outcomes and Real World Evidence (GPORWE) International, Windlesham, SurreyGU20 6PH, UK
Pages 395-403
|
Published online: 06 Jun 2019
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.